Key clinical point: Ultra-deep sequencing identified genetic mutations of the BCR/ABL1 tyrosine kinase domain in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CML-CP) receiving nilotinib that could have prognostic implications in predicting molecular response (MR) duration.

Major finding: V299 L mutation associated with dasatinib resistance and nilotinib sensitivity was observed in 98% of patients. Of all the detected mutations, only V371A mutation vs. no mutation was associated with shorter sustained major MR for 2 years (75% vs. 100%; P = .039) and sustained MR 4.5 for 15 months (25.0% vs. 94.1%; P = .002).

Study details: Findings are from a prospective analysis of 50 patients with newly diagnosed Ph+ CML-CP undergoing first-line nilotinib therapy.

Disclosures: This study was funded by Novartis Pharmaceuticals Corporation. The authors declared no conflict of interests.

Source: Park H et al. Leuk Res. 2021;111:106728 (Oct 15).Doi: 10.1016/j.leukres.2021.106728.

Key clinical point: Ultra-deep sequencing identified genetic mutations of the BCR/ABL1 tyrosine kinase domain in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CML-CP) receiving nilotinib that could have prognostic implications in predicting molecular response (MR) duration.

Major finding: V299 L mutation associated with dasatinib resistance and nilotinib sensitivity was observed in 98% of patients. Of all the detected mutations, only V371A mutation vs. no mutation was associated with shorter sustained major MR for 2 years (75% vs. 100%; P = .039) and sustained MR 4.5 for 15 months (25.0% vs. 94.1%; P = .002).

Study details: Findings are from a prospective analysis of 50 patients with newly diagnosed Ph+ CML-CP undergoing first-line nilotinib therapy.

Disclosures: This study was funded by Novartis Pharmaceuticals Corporation. The authors declared no conflict of interests.

Source: Park H et al. Leuk Res. 2021;111:106728 (Oct 15).Doi: 10.1016/j.leukres.2021.106728.

Key clinical point: Ultra-deep sequencing identified genetic mutations of the BCR/ABL1 tyrosine kinase domain in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CML-CP) receiving nilotinib that could have prognostic implications in predicting molecular response (MR) duration.

Major finding: V299 L mutation associated with dasatinib resistance and nilotinib sensitivity was observed in 98% of patients. Of all the detected mutations, only V371A mutation vs. no mutation was associated with shorter sustained major MR for 2 years (75% vs. 100%; P = .039) and sustained MR 4.5 for 15 months (25.0% vs. 94.1%; P = .002).

Study details: Findings are from a prospective analysis of 50 patients with newly diagnosed Ph+ CML-CP undergoing first-line nilotinib therapy.

Disclosures: This study was funded by Novartis Pharmaceuticals Corporation. The authors declared no conflict of interests.

Source: Park H et al. Leuk Res. 2021;111:106728 (Oct 15).Doi: 10.1016/j.leukres.2021.106728.

Key clinical point: Monitoring routine plasma levels of imatinib may help optimize treatment dosage, thereby enabling treatment individualization and improving clinical outcomes in patients with chronic myeloid leukemia (CML).

Major finding: Only 39.3% patients showed minimum imatinib plasma concentrations measured at steady state (Cssmin) within therapeutic range (750-1500 ng/mL). Optimal molecular response was achieved by 100% vs. 50% of patients with Cssmin ≥750 ng/mL vs. <750 ng/mL (P = .0004). The rate of toxicity was higher in patients with Cssmin >1500 ng/mL vs. ≤1500 ng/mL (36.4% vs. 5.9%; P = .039).

Study details: This cross-sectional study included 28 patients with CML treated with imatinib for >1 month.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Del Rosario García B et al. J Oncol Pharm Pract. 2021 (Oct 18). Doi: 10.1177/10781552211052535.

Key clinical point: Monitoring routine plasma levels of imatinib may help optimize treatment dosage, thereby enabling treatment individualization and improving clinical outcomes in patients with chronic myeloid leukemia (CML).

Major finding: Only 39.3% patients showed minimum imatinib plasma concentrations measured at steady state (Cssmin) within therapeutic range (750-1500 ng/mL). Optimal molecular response was achieved by 100% vs. 50% of patients with Cssmin ≥750 ng/mL vs. <750 ng/mL (P = .0004). The rate of toxicity was higher in patients with Cssmin >1500 ng/mL vs. ≤1500 ng/mL (36.4% vs. 5.9%; P = .039).

Study details: This cross-sectional study included 28 patients with CML treated with imatinib for >1 month.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Del Rosario García B et al. J Oncol Pharm Pract. 2021 (Oct 18). Doi: 10.1177/10781552211052535.

Key clinical point: Monitoring routine plasma levels of imatinib may help optimize treatment dosage, thereby enabling treatment individualization and improving clinical outcomes in patients with chronic myeloid leukemia (CML).

Major finding: Only 39.3% patients showed minimum imatinib plasma concentrations measured at steady state (Cssmin) within therapeutic range (750-1500 ng/mL). Optimal molecular response was achieved by 100% vs. 50% of patients with Cssmin ≥750 ng/mL vs. <750 ng/mL (P = .0004). The rate of toxicity was higher in patients with Cssmin >1500 ng/mL vs. ≤1500 ng/mL (36.4% vs. 5.9%; P = .039).

Study details: This cross-sectional study included 28 patients with CML treated with imatinib for >1 month.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Del Rosario García B et al. J Oncol Pharm Pract. 2021 (Oct 18). Doi: 10.1177/10781552211052535.

Key clinical point: Suboptimal adherence to oral anticancer (OAC) agents was observed among patients with chronic myeloid leukemia (CML), highlighting the need for implementation of personalized counseling to address the risk for nonadherence and enhance treatment outcomes.

Major finding: Almost 17.9% of participants reported nonadherence, i.e., missing at least 1 dose of CML medication in the previous week. Patients who missed at least 1 vs. 0 doses in the last 7 days reported that medication was somewhat to very hard to take (50.0% vs. 18.6%; P = .008) or they missed doses because of side effects (50.0% vs. 11.4%; P = .001) or busy schedule (37.5% vs. 2.9%; P = .004).

Study details: This study included 86 adult patients with CML with a prescription of OAC agents (imatinib, nilotinib, dasatinib, bosutinib, or ponatinib) for at least 30 days.

Disclosures: This study was funded by grants from the National Cancer Institute and partly by the Institute of General Medical Sciences of the National Institutes of Health. The authors declared no conflict of interests.

Source: Davis TC et al. Int J Environ Res Public Health. 2021;18(21):11045 (Oct 21). Doi: 10.3390/ijerph182111045.

Key clinical point: Suboptimal adherence to oral anticancer (OAC) agents was observed among patients with chronic myeloid leukemia (CML), highlighting the need for implementation of personalized counseling to address the risk for nonadherence and enhance treatment outcomes.

Major finding: Almost 17.9% of participants reported nonadherence, i.e., missing at least 1 dose of CML medication in the previous week. Patients who missed at least 1 vs. 0 doses in the last 7 days reported that medication was somewhat to very hard to take (50.0% vs. 18.6%; P = .008) or they missed doses because of side effects (50.0% vs. 11.4%; P = .001) or busy schedule (37.5% vs. 2.9%; P = .004).

Study details: This study included 86 adult patients with CML with a prescription of OAC agents (imatinib, nilotinib, dasatinib, bosutinib, or ponatinib) for at least 30 days.

Disclosures: This study was funded by grants from the National Cancer Institute and partly by the Institute of General Medical Sciences of the National Institutes of Health. The authors declared no conflict of interests.

Source: Davis TC et al. Int J Environ Res Public Health. 2021;18(21):11045 (Oct 21). Doi: 10.3390/ijerph182111045.

Key clinical point: Suboptimal adherence to oral anticancer (OAC) agents was observed among patients with chronic myeloid leukemia (CML), highlighting the need for implementation of personalized counseling to address the risk for nonadherence and enhance treatment outcomes.

Major finding: Almost 17.9% of participants reported nonadherence, i.e., missing at least 1 dose of CML medication in the previous week. Patients who missed at least 1 vs. 0 doses in the last 7 days reported that medication was somewhat to very hard to take (50.0% vs. 18.6%; P = .008) or they missed doses because of side effects (50.0% vs. 11.4%; P = .001) or busy schedule (37.5% vs. 2.9%; P = .004).

Study details: This study included 86 adult patients with CML with a prescription of OAC agents (imatinib, nilotinib, dasatinib, bosutinib, or ponatinib) for at least 30 days.

Disclosures: This study was funded by grants from the National Cancer Institute and partly by the Institute of General Medical Sciences of the National Institutes of Health. The authors declared no conflict of interests.

Source: Davis TC et al. Int J Environ Res Public Health. 2021;18(21):11045 (Oct 21). Doi: 10.3390/ijerph182111045.

Key clinical point: Cardiovascular risk stratification based on age, history of prior cardiovascular diseases, and Framingham risk score, along with additional insights from coronary artery calcium scoring (CACS), was feasible in patients with chronic myeloid leukemia (CML) treated with any tyrosine kinase inhibitors (TKI).

Major finding: During a median follow-up of 3.8 years, rates of major adverse cardiovascular events (MACE) in study-defined low-, intermediate-, and high-risk groups were 0%, 10%, and 19%, respectively. None of the patients reclassified from intermediate to low risk by CACS experienced MACE.

Study details: This retrospective study included 88 patients with CML treated with any TKI.

Disclosures: No specific source of funding was identified. Some investigators, including the lead author, reported receiving honoraria and consultancy fees or serving on advisory boards of various pharmaceutical companies.

Source: Baggio D et al. Intern Med J. 2021;51(10):1736-40 (Oct 18). Doi: 10.1111/imj.15517.

Key clinical point: Cardiovascular risk stratification based on age, history of prior cardiovascular diseases, and Framingham risk score, along with additional insights from coronary artery calcium scoring (CACS), was feasible in patients with chronic myeloid leukemia (CML) treated with any tyrosine kinase inhibitors (TKI).

Major finding: During a median follow-up of 3.8 years, rates of major adverse cardiovascular events (MACE) in study-defined low-, intermediate-, and high-risk groups were 0%, 10%, and 19%, respectively. None of the patients reclassified from intermediate to low risk by CACS experienced MACE.

Study details: This retrospective study included 88 patients with CML treated with any TKI.

Disclosures: No specific source of funding was identified. Some investigators, including the lead author, reported receiving honoraria and consultancy fees or serving on advisory boards of various pharmaceutical companies.

Source: Baggio D et al. Intern Med J. 2021;51(10):1736-40 (Oct 18). Doi: 10.1111/imj.15517.

Key clinical point: Cardiovascular risk stratification based on age, history of prior cardiovascular diseases, and Framingham risk score, along with additional insights from coronary artery calcium scoring (CACS), was feasible in patients with chronic myeloid leukemia (CML) treated with any tyrosine kinase inhibitors (TKI).

Major finding: During a median follow-up of 3.8 years, rates of major adverse cardiovascular events (MACE) in study-defined low-, intermediate-, and high-risk groups were 0%, 10%, and 19%, respectively. None of the patients reclassified from intermediate to low risk by CACS experienced MACE.

Study details: This retrospective study included 88 patients with CML treated with any TKI.

Disclosures: No specific source of funding was identified. Some investigators, including the lead author, reported receiving honoraria and consultancy fees or serving on advisory boards of various pharmaceutical companies.

Source: Baggio D et al. Intern Med J. 2021;51(10):1736-40 (Oct 18). Doi: 10.1111/imj.15517.

Key clinical point: Compared with 90% adherence, a 100% adherence to imatinib was associated with a 2-fold increase in achieving or maintaining treatment response in patients with chronic myeloid leukemia (CML), highlighting the urgent need to assess and promote patient adherence.

Major finding: A 90-day imatinib pill-count adherence of 100% vs. 90% increased the probabilities of achieving complete hematological response by 2.25-fold (probability of treatment response [pTR] 0.8416 vs. 0.3746), complete cytogenic response by 2.24-fold (pTR 0.8335 vs. 0.3714), major molecular response by 1.95-fold (pTR 0.7698 vs. 0.3938), and optimal response by 2.35-fold (pTR 0.8236 vs. 0.3512).

Study details: Findings are from a post hoc analysis of the ADAGIO study including 169 patients with CML.

Disclosures: This study did not receive any specific funding. Some investigators reported being equity shareholders and employees of or receiving honoraria from various sources including Novartis which funded the ADAGIO study.

Source: Obeng-Kusi M et al. Leuk Res. 2021;111:106734 (Oct 21). Doi: 10.1016/j.leukres.2021.106734.

Key clinical point: Compared with 90% adherence, a 100% adherence to imatinib was associated with a 2-fold increase in achieving or maintaining treatment response in patients with chronic myeloid leukemia (CML), highlighting the urgent need to assess and promote patient adherence.

Major finding: A 90-day imatinib pill-count adherence of 100% vs. 90% increased the probabilities of achieving complete hematological response by 2.25-fold (probability of treatment response [pTR] 0.8416 vs. 0.3746), complete cytogenic response by 2.24-fold (pTR 0.8335 vs. 0.3714), major molecular response by 1.95-fold (pTR 0.7698 vs. 0.3938), and optimal response by 2.35-fold (pTR 0.8236 vs. 0.3512).

Study details: Findings are from a post hoc analysis of the ADAGIO study including 169 patients with CML.

Disclosures: This study did not receive any specific funding. Some investigators reported being equity shareholders and employees of or receiving honoraria from various sources including Novartis which funded the ADAGIO study.

Source: Obeng-Kusi M et al. Leuk Res. 2021;111:106734 (Oct 21). Doi: 10.1016/j.leukres.2021.106734.

Key clinical point: Compared with 90% adherence, a 100% adherence to imatinib was associated with a 2-fold increase in achieving or maintaining treatment response in patients with chronic myeloid leukemia (CML), highlighting the urgent need to assess and promote patient adherence.

Major finding: A 90-day imatinib pill-count adherence of 100% vs. 90% increased the probabilities of achieving complete hematological response by 2.25-fold (probability of treatment response [pTR] 0.8416 vs. 0.3746), complete cytogenic response by 2.24-fold (pTR 0.8335 vs. 0.3714), major molecular response by 1.95-fold (pTR 0.7698 vs. 0.3938), and optimal response by 2.35-fold (pTR 0.8236 vs. 0.3512).

Study details: Findings are from a post hoc analysis of the ADAGIO study including 169 patients with CML.

Disclosures: This study did not receive any specific funding. Some investigators reported being equity shareholders and employees of or receiving honoraria from various sources including Novartis which funded the ADAGIO study.

Source: Obeng-Kusi M et al. Leuk Res. 2021;111:106734 (Oct 21). Doi: 10.1016/j.leukres.2021.106734.

Key clinical point: Exocrine pancreatic insufficiency (EPI) is the major cause of nutrient malabsorption in cystic fibrosis (CF), with the likelihood of restoration of pancreatic function significantly higher if CF transmembrane conductance regulator (CFTR) modulator therapies are initiated as early in life as possible.

Main finding: In the ARRIVAL study, ivacaftor led to a mean decrease of 56% in immunoreactive trypsinogen in 12-24 month old patients with CFTR gating mutation. Similar improvements were observed in older children aged 2-5 years treated with ivacaftor in the KIWI and the open-label extension KLIMB study. However, the results are not as promising in older patients aged 5-61 years.

Study details: These are highlights from a review that summarizes the effects of highly effective CFTR modulators on growth and nutrition in patients with CF.

Disclosures: The manuscript did not receive any additional funding. The authors declared receiving grant support and serving as consultants for various sources.

Source: Bass R et al. Nutrients. 2021(Aug 24);13(9):2907. Doi: 10.3390/nu13092907.

Key clinical point: Exocrine pancreatic insufficiency (EPI) is the major cause of nutrient malabsorption in cystic fibrosis (CF), with the likelihood of restoration of pancreatic function significantly higher if CF transmembrane conductance regulator (CFTR) modulator therapies are initiated as early in life as possible.

Main finding: In the ARRIVAL study, ivacaftor led to a mean decrease of 56% in immunoreactive trypsinogen in 12-24 month old patients with CFTR gating mutation. Similar improvements were observed in older children aged 2-5 years treated with ivacaftor in the KIWI and the open-label extension KLIMB study. However, the results are not as promising in older patients aged 5-61 years.

Study details: These are highlights from a review that summarizes the effects of highly effective CFTR modulators on growth and nutrition in patients with CF.

Disclosures: The manuscript did not receive any additional funding. The authors declared receiving grant support and serving as consultants for various sources.

Source: Bass R et al. Nutrients. 2021(Aug 24);13(9):2907. Doi: 10.3390/nu13092907.

Key clinical point: Exocrine pancreatic insufficiency (EPI) is the major cause of nutrient malabsorption in cystic fibrosis (CF), with the likelihood of restoration of pancreatic function significantly higher if CF transmembrane conductance regulator (CFTR) modulator therapies are initiated as early in life as possible.

Main finding: In the ARRIVAL study, ivacaftor led to a mean decrease of 56% in immunoreactive trypsinogen in 12-24 month old patients with CFTR gating mutation. Similar improvements were observed in older children aged 2-5 years treated with ivacaftor in the KIWI and the open-label extension KLIMB study. However, the results are not as promising in older patients aged 5-61 years.

Study details: These are highlights from a review that summarizes the effects of highly effective CFTR modulators on growth and nutrition in patients with CF.

Disclosures: The manuscript did not receive any additional funding. The authors declared receiving grant support and serving as consultants for various sources.

Source: Bass R et al. Nutrients. 2021(Aug 24);13(9):2907. Doi: 10.3390/nu13092907.

Key clinical point: Pancreatic enzyme replacement therapy (PERT) administration in patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing standard first-line chemotherapy with gemcitabine plus nab-paclitaxel improved survival, along with weight gain and reduction in maldigestion-related symptoms.

Major finding: PERT administration was associated with longer overall survival (hazard ratio 2.85; P < .001), weight gain at 3 months (P = .02), and a significant reduction in feeling of indigestion (P = .001), bloating (P < .0001), frequent stools (P < .0001), and floating or greasy/fatty stool (P = .003).

Study details: This retrospective study included 110 patients with advanced PDAC treated with first-line chemotherapy with gemcitabine plus nab-paclitaxel with (n = 55) or without (n = 55) PERT administration.

Disclosures: No specific source of funding was identified for this study. Some investigators, including the lead author, reported receiving speaker’s fees, honoraria, travel expenses, consultant’s fees, and institutional research grants and participation in advisory boards and steering committee activities from various sources.

Source: Trestini I et al. Front Oncol. 2021(Sep 9).Doi: 10.3389/fonc.2021.688889.

Key clinical point: Pancreatic enzyme replacement therapy (PERT) administration in patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing standard first-line chemotherapy with gemcitabine plus nab-paclitaxel improved survival, along with weight gain and reduction in maldigestion-related symptoms.

Major finding: PERT administration was associated with longer overall survival (hazard ratio 2.85; P < .001), weight gain at 3 months (P = .02), and a significant reduction in feeling of indigestion (P = .001), bloating (P < .0001), frequent stools (P < .0001), and floating or greasy/fatty stool (P = .003).

Study details: This retrospective study included 110 patients with advanced PDAC treated with first-line chemotherapy with gemcitabine plus nab-paclitaxel with (n = 55) or without (n = 55) PERT administration.

Disclosures: No specific source of funding was identified for this study. Some investigators, including the lead author, reported receiving speaker’s fees, honoraria, travel expenses, consultant’s fees, and institutional research grants and participation in advisory boards and steering committee activities from various sources.

Source: Trestini I et al. Front Oncol. 2021(Sep 9).Doi: 10.3389/fonc.2021.688889.

Key clinical point: Pancreatic enzyme replacement therapy (PERT) administration in patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing standard first-line chemotherapy with gemcitabine plus nab-paclitaxel improved survival, along with weight gain and reduction in maldigestion-related symptoms.

Major finding: PERT administration was associated with longer overall survival (hazard ratio 2.85; P < .001), weight gain at 3 months (P = .02), and a significant reduction in feeling of indigestion (P = .001), bloating (P < .0001), frequent stools (P < .0001), and floating or greasy/fatty stool (P = .003).

Study details: This retrospective study included 110 patients with advanced PDAC treated with first-line chemotherapy with gemcitabine plus nab-paclitaxel with (n = 55) or without (n = 55) PERT administration.

Disclosures: No specific source of funding was identified for this study. Some investigators, including the lead author, reported receiving speaker’s fees, honoraria, travel expenses, consultant’s fees, and institutional research grants and participation in advisory boards and steering committee activities from various sources.

Source: Trestini I et al. Front Oncol. 2021(Sep 9).Doi: 10.3389/fonc.2021.688889.

Key clinical point: Elevated serum amylase (ESA) was associated with adverse clinical outcomes and mortality in hospitalized patients with COVID-19.

Major finding: Hyperamylasemia (amylase > upper limit of normal [ULN] of 115 U/L) was independently associated with mortality (1-3-times ULN [1-3 ULN]: hazard ratio [HR] 1.63; P = .034; >3-fold ULN [>3 ULN]: HR 8.90; P < .001) and adverse outcomes (all P < .001), such as sepsis (1-3 ULN: odds ratio [OR] 1.15; >3 ULN: OR 1.87), disseminated intravascular coagulation (1-3 ULN: OR 1.13; >3 ULN: OR 1.65), cardiac injury (1-3 ULN: OR 1.24; >3 ULN: OR 1.71), acute respiratory distress syndrome (1-3 ULN: OR 1.21; >3 ULN: OR 1.62), and acute kidney injury (1-3 ULN: OR 1.24; >3 ULN: OR 1.79).

Study details: This retrospective study included 1,515 inpatients with COVID-19. Overall, 196 patients had ESA, of which 9.7% had an ESA of >3 ULN.

Disclosures: This study was supported by the National Nature Science Foundation of China and Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province. The authors declared no conflict of interests.

Source: Li G et al. Aging (Albany NY). 2021(Oct 29);13(20):23442-23458. Doi: 10.18632/aging.203653.

Key clinical point: Elevated serum amylase (ESA) was associated with adverse clinical outcomes and mortality in hospitalized patients with COVID-19.

Major finding: Hyperamylasemia (amylase > upper limit of normal [ULN] of 115 U/L) was independently associated with mortality (1-3-times ULN [1-3 ULN]: hazard ratio [HR] 1.63; P = .034; >3-fold ULN [>3 ULN]: HR 8.90; P < .001) and adverse outcomes (all P < .001), such as sepsis (1-3 ULN: odds ratio [OR] 1.15; >3 ULN: OR 1.87), disseminated intravascular coagulation (1-3 ULN: OR 1.13; >3 ULN: OR 1.65), cardiac injury (1-3 ULN: OR 1.24; >3 ULN: OR 1.71), acute respiratory distress syndrome (1-3 ULN: OR 1.21; >3 ULN: OR 1.62), and acute kidney injury (1-3 ULN: OR 1.24; >3 ULN: OR 1.79).

Study details: This retrospective study included 1,515 inpatients with COVID-19. Overall, 196 patients had ESA, of which 9.7% had an ESA of >3 ULN.

Disclosures: This study was supported by the National Nature Science Foundation of China and Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province. The authors declared no conflict of interests.

Source: Li G et al. Aging (Albany NY). 2021(Oct 29);13(20):23442-23458. Doi: 10.18632/aging.203653.

Key clinical point: Elevated serum amylase (ESA) was associated with adverse clinical outcomes and mortality in hospitalized patients with COVID-19.

Major finding: Hyperamylasemia (amylase > upper limit of normal [ULN] of 115 U/L) was independently associated with mortality (1-3-times ULN [1-3 ULN]: hazard ratio [HR] 1.63; P = .034; >3-fold ULN [>3 ULN]: HR 8.90; P < .001) and adverse outcomes (all P < .001), such as sepsis (1-3 ULN: odds ratio [OR] 1.15; >3 ULN: OR 1.87), disseminated intravascular coagulation (1-3 ULN: OR 1.13; >3 ULN: OR 1.65), cardiac injury (1-3 ULN: OR 1.24; >3 ULN: OR 1.71), acute respiratory distress syndrome (1-3 ULN: OR 1.21; >3 ULN: OR 1.62), and acute kidney injury (1-3 ULN: OR 1.24; >3 ULN: OR 1.79).

Study details: This retrospective study included 1,515 inpatients with COVID-19. Overall, 196 patients had ESA, of which 9.7% had an ESA of >3 ULN.

Disclosures: This study was supported by the National Nature Science Foundation of China and Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province. The authors declared no conflict of interests.

Source: Li G et al. Aging (Albany NY). 2021(Oct 29);13(20):23442-23458. Doi: 10.18632/aging.203653.

Key clinical point: An increased intrapancreatic fat deposition (IPFD) following acute pancreatitis (AP) was associated with a decrease in pancreatic tail diameter (PTD), and in turn, decreased circulating levels of pancreatic amylase.

Major finding: An increased IPFD was significantly associated with reduced PTD in patients with AP (P = .036). Pancreatic amylase was associated with PTD in AP (P = .042).

Study details: This cross-sectional study included 108 individuals with previous AP (median, 20 months post-AP) and 60 healthy controls.

Disclosures: This study was supported by the Rutherford Discovery Fellowship by the Royal Society of New Zealand to MS Petrov. The authors declared no conflict of interests.

Source: Ko J et al. Obes Facts. 2021(Nov 9). Doi: 10.1159/000519621.

Key clinical point: An increased intrapancreatic fat deposition (IPFD) following acute pancreatitis (AP) was associated with a decrease in pancreatic tail diameter (PTD), and in turn, decreased circulating levels of pancreatic amylase.

Major finding: An increased IPFD was significantly associated with reduced PTD in patients with AP (P = .036). Pancreatic amylase was associated with PTD in AP (P = .042).

Study details: This cross-sectional study included 108 individuals with previous AP (median, 20 months post-AP) and 60 healthy controls.

Disclosures: This study was supported by the Rutherford Discovery Fellowship by the Royal Society of New Zealand to MS Petrov. The authors declared no conflict of interests.

Source: Ko J et al. Obes Facts. 2021(Nov 9). Doi: 10.1159/000519621.

Key clinical point: An increased intrapancreatic fat deposition (IPFD) following acute pancreatitis (AP) was associated with a decrease in pancreatic tail diameter (PTD), and in turn, decreased circulating levels of pancreatic amylase.

Major finding: An increased IPFD was significantly associated with reduced PTD in patients with AP (P = .036). Pancreatic amylase was associated with PTD in AP (P = .042).

Study details: This cross-sectional study included 108 individuals with previous AP (median, 20 months post-AP) and 60 healthy controls.

Disclosures: This study was supported by the Rutherford Discovery Fellowship by the Royal Society of New Zealand to MS Petrov. The authors declared no conflict of interests.

Source: Ko J et al. Obes Facts. 2021(Nov 9). Doi: 10.1159/000519621.

Key clinical point: Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator use was associated with reduced incidence of acute pancreatitis (AP) hospitalizations in pancreas-sufficient (PS) and pancreas-insufficient (PI) patients with CF.

Major finding: Estimated rates of AP hospitalizations per 1000 patient-years in patients with PS-CF and PI-CF treated with CFTR modulator were 3.26 (95% CI 0.94-11.33) and 0.66 (95% CI 0.26-1.68), respectively, and those not treated with CFTR modulator were 10.20 (95% CI 6.19-16.81) and 1.76 (95% CI 0.98-3.17), respectively.

Study details: Findings are from a retrospective analysis of 10,417 patients with CF (PS n = 3,759; PI n = 6,658) with (17.2%) or without previous CFTR modulator use.

Disclosures: This study was supported by the US National Center for Advancing Translational Sciences. The authors declared no conflict of interests.

Source: Ramsey ML et al. Am J Gastroenterol. 2021(Oct 19). Doi: 10.14309/ajg.0000000000001527.

Key clinical point: Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator use was associated with reduced incidence of acute pancreatitis (AP) hospitalizations in pancreas-sufficient (PS) and pancreas-insufficient (PI) patients with CF.

Major finding: Estimated rates of AP hospitalizations per 1000 patient-years in patients with PS-CF and PI-CF treated with CFTR modulator were 3.26 (95% CI 0.94-11.33) and 0.66 (95% CI 0.26-1.68), respectively, and those not treated with CFTR modulator were 10.20 (95% CI 6.19-16.81) and 1.76 (95% CI 0.98-3.17), respectively.

Study details: Findings are from a retrospective analysis of 10,417 patients with CF (PS n = 3,759; PI n = 6,658) with (17.2%) or without previous CFTR modulator use.

Disclosures: This study was supported by the US National Center for Advancing Translational Sciences. The authors declared no conflict of interests.

Source: Ramsey ML et al. Am J Gastroenterol. 2021(Oct 19). Doi: 10.14309/ajg.0000000000001527.

Key clinical point: Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator use was associated with reduced incidence of acute pancreatitis (AP) hospitalizations in pancreas-sufficient (PS) and pancreas-insufficient (PI) patients with CF.

Major finding: Estimated rates of AP hospitalizations per 1000 patient-years in patients with PS-CF and PI-CF treated with CFTR modulator were 3.26 (95% CI 0.94-11.33) and 0.66 (95% CI 0.26-1.68), respectively, and those not treated with CFTR modulator were 10.20 (95% CI 6.19-16.81) and 1.76 (95% CI 0.98-3.17), respectively.

Study details: Findings are from a retrospective analysis of 10,417 patients with CF (PS n = 3,759; PI n = 6,658) with (17.2%) or without previous CFTR modulator use.

Disclosures: This study was supported by the US National Center for Advancing Translational Sciences. The authors declared no conflict of interests.

Source: Ramsey ML et al. Am J Gastroenterol. 2021(Oct 19). Doi: 10.14309/ajg.0000000000001527.